Plus Therapeutics (PSTV)’ wholly-owned subsidiary CNSide Diagnostics has been granted lab licenses to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test in California, Rhode Island and Maryland. The CNSide CSF Assay Platform supports diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. More than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020. This test is available exclusively through CNSide Diagnostics as a testing service provided to health care professionals in the U.S. CNSide Diagnostics performs the tests in its CLIA certified facility in Houston, TX.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics announces expansion of CNSide Team
- Plus Therapeutics presents REYOBIQ data at WFNOS/SNO annual meeting
- Strategic Advancements and Market Expansion Drive Plus Therapeutics’ Buy Rating
- Plus Therapeutics completes FDA meeting on REYOBIQ development plans
- Strategic Advancements and Expanding Coverage Propel Plus Therapeutics’ Growth Potential